Impact Biomedical Announces Positive Results from its In-Vitro Testing of Equivir and Linebacker, its Compounds for the Treatment of COVID-19

Stock Information for DSS Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DSS Inc.

Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose(TM) Technology Entitled "Low Glycemic Sugar Composition."
DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market
Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years
Impact Biomedical Inc. Files Current Report on Form 8-K
DSS Inc. Wins Patent Dispute with Nichia Corporation
DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder's Common Stock
DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule
DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.